NCT04803318

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Detailed description

The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.

Conditions

• Solid Tumor, Adult
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Combination of three inhibitors Trametinib, Everolimus and Lenvatinib	Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Timeline

• Start date: 2021-01-01
• Primary completion: 2029-01-01
• Completion: 2037-01-01
• First posted: 2021-03-17
• Last updated: 2024-06-25

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study